Turner, E. H., A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358(3):252-260.

Unger, E. 2010. Memorandum to the file regarding NDA: 21-071; suppl 35, 36, 37 Avandia (rosiglitazone). In FDA Briefing Document: Advisory Committee Meeting for NDA 21071: Avandia (rosiglitazone maleate) tablet: July 13 and 14, 2010. Washington, DC: Department of Health and Human Services.

Vandenbroucke, J. P. 2006. What is the best evidence for determining harms of medical treatment? Canadian Medical Association Journal 174(5):645-646.

Vandenbroucke, J. P., and B. M. Psaty. 2008. Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA 300(20):2417-2419.

Vedula, S. S., L. Bero, R. W. Scherer, and K. Dickersin. 2009. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. New England Journal of Medicine 361(20):1963-1971.

Weiss, N. S., T. D. Koepsell, and B. M. Psaty. 2008. Generalizability of the results of randomized trials. Archives of Internal Medicine 168(2):133-135.

Wood, A. J. J. 2009. Progress and deficiencies in the registration of clinical trials. New England Journal of Medicine 360(8):824-830.

Yap, J. S. 2010. Statistical review and evaluation: Clinical studies NDA 21-071/35 and 21-073. In FDA Briefing Document Advisory Committee Meeting for NDA 21071: Avandia (rosiglitazone maleate) tablet: July 13 and 14, 2010. Washington, DC: Department of Health and Human Services.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement